Related Experiment Videos
Fluphenazine plasma levels and clinical response
The Journal of Clinical Psychiatry
|September 1, 1984
Summary
This study found a therapeutic range for fluphenazine plasma levels in schizophrenia patients. Achieving optimal fluphenazine levels correlated with significantly greater clinical improvement, suggesting a target range for treatment.
Area of Science:
- Pharmacology
- Psychiatry
- Clinical Neuroscience
Background:
- Schizophrenia treatment often involves antipsychotic medications like fluphenazine.
- Determining optimal plasma concentrations for antipsychotics is crucial for effective treatment and minimizing side effects.
Purpose of the Study:
- To investigate the relationship between plasma fluphenazine levels and clinical response in schizophrenic patients.
- To establish a potential therapeutic window for fluphenazine plasma concentrations.
Main Methods:
- A steady-state methodology was employed to measure plasma fluphenazine levels.
- Nineteen inpatient schizophrenic patients (DSM-III diagnoses) received constant fluphenazine doses.
- Clinical response was assessed in relation to measured plasma drug levels.
Main Results:
- A significant curvilinear correlation was observed between clinical response and steady-state plasma fluphenazine levels (p < .05).
- A therapeutic range of 0.13–0.70 ng/ml for plasma fluphenazine is proposed.
- Patients within the proposed therapeutic range showed a 59% mean clinical improvement, versus 34% for those above 0.70 ng/ml (p < .01).
Conclusions:
- Plasma fluphenazine levels are significantly correlated with clinical outcomes in schizophrenia.
- The findings suggest a therapeutic range for fluphenazine, guiding optimal dosing strategies.
- Monitoring plasma fluphenazine levels may enhance treatment efficacy in schizophrenia management.